DBV Technologies (NASDAQ:DBVT) Receives Market Outperform Rating from JMP Securities

DBV Technologies (NASDAQ:DBVT)‘s stock had its “market outperform” rating reaffirmed by stock analysts at JMP Securities in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $10.00 price objective on the stock. JMP Securities’ target price would suggest a potential upside of 141.55% from the stock’s current price.

DBVT has been the subject of a number of other reports. HC Wainwright lifted their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th. StockNews.com assumed coverage on shares of DBV Technologies in a research note on Thursday. They set a “hold” rating for the company.

DBV Technologies Price Performance

NASDAQ DBVT traded up $0.31 during trading hours on Friday, hitting $4.14. The company’s stock had a trading volume of 422,393 shares, compared to its average volume of 282,508. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $9.49. The company’s 50 day simple moving average is $3.29 and its two-hundred day simple moving average is $3.82. The company has a market cap of $85.16 million, a P/E ratio of -0.92 and a beta of 0.64.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.